PT3116887T - Ligantes de hidratos de carbono que se ligam a anticorpos igm contra a glicoproteína associada à mielina - Google Patents

Ligantes de hidratos de carbono que se ligam a anticorpos igm contra a glicoproteína associada à mielina

Info

Publication number
PT3116887T
PT3116887T PT157094830T PT15709483T PT3116887T PT 3116887 T PT3116887 T PT 3116887T PT 157094830 T PT157094830 T PT 157094830T PT 15709483 T PT15709483 T PT 15709483T PT 3116887 T PT3116887 T PT 3116887T
Authority
PT
Portugal
Prior art keywords
bind
antibodies against
igm antibodies
associated glycoprotein
carbohydrate ligands
Prior art date
Application number
PT157094830T
Other languages
English (en)
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of PT3116887T publication Critical patent/PT3116887T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/10—Esters
    • C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00—Processes of polymerisation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/02—Food
    • G01N33/04—Dairy products
    • G01N33/06—Determining fat content, e.g. by butyrometer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
PT157094830T 2014-03-13 2015-03-12 Ligantes de hidratos de carbono que se ligam a anticorpos igm contra a glicoproteína associada à mielina PT3116887T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14159528 2014-03-13

Publications (1)

Publication Number Publication Date
PT3116887T true PT3116887T (pt) 2021-04-30

Family

ID=50241299

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157094830T PT3116887T (pt) 2014-03-13 2015-03-12 Ligantes de hidratos de carbono que se ligam a anticorpos igm contra a glicoproteína associada à mielina

Country Status (22)

Country Link
US (4) US9994605B2 (pt)
EP (2) EP3116887B1 (pt)
JP (1) JP6502374B2 (pt)
KR (1) KR20160132034A (pt)
CN (2) CN106103461B (pt)
AU (2) AU2015228870B2 (pt)
CA (1) CA2940579A1 (pt)
CY (1) CY1124344T1 (pt)
DK (1) DK3116887T3 (pt)
ES (1) ES2865148T3 (pt)
HR (1) HRP20210562T1 (pt)
HU (1) HUE054034T2 (pt)
IL (1) IL247355B (pt)
LT (1) LT3116887T (pt)
MX (1) MX2016011859A (pt)
PL (1) PL3116887T3 (pt)
PT (1) PT3116887T (pt)
RS (1) RS61722B1 (pt)
RU (1) RU2760005C2 (pt)
SG (1) SG11201607484RA (pt)
SI (1) SI3116887T1 (pt)
WO (1) WO2015136027A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3116887T3 (da) 2014-03-13 2021-04-26 Univ Basel Carbonhydratligander, der binder til igm-antistoffer mod myelin-associeret glykoprotein
CN108026134A (zh) 2015-09-16 2018-05-11 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
WO2018167230A1 (en) * 2017-03-15 2018-09-20 Polyneuron Pharmaceuticals Ag Glycopolymers sequestering carbohydrate-binding proteins
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
WO2022063879A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
JP2023542388A (ja) 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー 第ｖｉｉｉ因子補充療法の有効性を増加させるための化合物
AU2021347583A1 (en) 2020-09-23 2023-05-25 Ablevia Biotech Gmbh Compound for increasing efficacy of viral vectors
CA3192740A1 (en) 2020-09-23 2022-03-31 Oskar SMRZKA Compound for the prevention or treatment of autoantibody-mediated conditions
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
CN116710143A (zh) 2020-09-24 2023-09-05 艾柏力维亚生技有限公司 用于预防或治疗重症肌无力的化合物
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2811494B2 (ja) 1990-03-14 1998-10-15 富士写真フイルム株式会社 キトサンまたはキチン化合物を含有するハロゲン化銀写真感光材料およびこれを用いるハロゲン化銀写真感光材料の処理方法
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
JPH07502011A (ja) 1991-06-10 1995-03-02 グライカムド　インコーポレイテッド 免疫抑制性および寛容原性のオリゴ糖誘導体
US6020140A (en) 1991-08-09 2000-02-01 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
WO1993003375A1 (en) 1991-08-09 1993-02-18 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
US5985578A (en) 1991-08-09 1999-11-16 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
WO1993003735A1 (en) 1991-08-23 1993-03-04 Alberta Research Council Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
EP0601417A3 (de) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
CA2133772A1 (en) 1993-11-19 1995-05-20 Yuji Yamada Method for assaying glycoconjugate and reagent thereof
US5783693A (en) 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
DE19526675A1 (de) 1994-09-09 1996-03-14 Herbert Prof Dr Wiegandt Teststreifenanalyse zur Erfassung von autoallergen menschlichen Pathologien
FR2727117A1 (fr) 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
DE19531346A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
AU6858596A (en) * 1995-08-25 1997-03-19 Johns Hopkins University School Of Medicine, The Compounds for stimulating nerve growth
AU1122897A (en) 1995-11-13 1997-06-05 Glycomed Incorporated Novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties
US6677164B1 (en) 1995-11-21 2004-01-13 Novartis Ag Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds
US6491922B1 (en) 1996-02-09 2002-12-10 Cornell Research Foundation, Inc. Methods and compounds for treating autoimmune and vascular disease
DE69835201T2 (de) 1997-04-18 2007-06-14 Novartis Ag Neoglycoproteine
FR2762602B1 (fr) 1997-04-28 1999-06-04 Inst Nat Sante Rech Med Moyens pour la detection precoce de pathologies auto-immunes inflammatoires
US6077681A (en) 1997-06-30 2000-06-20 Washington University Diagnosis of motor neuropathy by detection of antibodies
JP2001515912A (ja) 1997-09-05 2001-09-25 グリシム オサケ ユキチュア 合成二価ｓＬｅｘ含有ポリラクトサミン類および使用法
ATE304865T1 (de) 1998-04-15 2005-10-15 Mayo Foundation Hemmung xenoreaktiver antikörper
JP2002511494A (ja) 1998-04-22 2002-04-16 メルク エンド カムパニー インコーポレーテッド 自己抗原断片、方法及びアッセイ
WO2000000516A1 (fr) 1998-06-30 2000-01-06 Mochida Pharmaceutical Co., Ltd. Nouveau peptide lie par une chaine de sucres et similaire a la thrombomoduline
US6228598B1 (en) * 1998-10-02 2001-05-08 Washington University Antibodies to heparan sulfate glycosaminoglycans in the diagnosis of polyneuropathies
CA2351146A1 (en) 1998-11-16 2000-05-25 Genetics Institute, Inc. The cxc chemokine h174 and methods for preventing damage to the nervous system
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
CA2353620A1 (en) 1998-12-09 2000-06-15 La Jolla Pharmaceutical Company Methods and formulations for reducing circulating antibodies
WO2000050447A1 (en) 1999-02-24 2000-08-31 Acorda Therapeutics Carbohydrate epitope mimic peptides and uses thereof
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
KR20020047177A (ko) 1999-09-21 2002-06-21 아피나 이문테히닉 게엠베하 확장성 심근질환을 유발하는 자동항체를 제거하기 위한펩티드
US7332168B2 (en) 2000-08-22 2008-02-19 Micromet Ag Composition for the elimination of autoreactive B-cells
WO2002018950A1 (en) 2000-08-28 2002-03-07 The Trustees Of Columbia University In The City Of New York Detection of anti-glycolipid antibodies by latex agglutination assay
WO2002038592A2 (de) 2000-11-08 2002-05-16 Affina Immuntechnik Gmbh Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6730487B2 (en) 2001-04-03 2004-05-04 Trustees Of Columbia University In The City Of New York Surface plasmon resonance biosensor for measurement of anti-glycolipid antibody levels in neuropathy
DE10127712A1 (de) 2001-06-07 2002-12-19 Torsten Witte Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis
DE60232077D1 (de) 2001-06-29 2009-06-04 Glykos Finland Oy Verwendung mindestens einer glycoinhibitor-substanz gegen infektionskrankheiten
US7323440B2 (en) 2002-02-13 2008-01-29 Micromet Ag De-immunized MOG (poly)peptide constructs
ES2297248T3 (es) 2002-08-02 2008-05-01 Glycominds Ltd. Procedimiento para diagnosticar esclerosis multiple.
RU2303461C9 (ru) * 2002-08-06 2007-12-27 Глаксо Груп Лимитед Антитела против миелин-ассоциированного гликопротеина (mag)
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
US7175989B2 (en) * 2002-08-20 2007-02-13 Alan Pestronk Antibodies to trisulfated heparin disaccharide in painful sensory axonal neuropathy
US20040043431A1 (en) 2002-08-29 2004-03-04 Aristo Vojdani Diagnosis of multiple sclerosis and other demyelinating diseases
US20030049692A1 (en) 2002-09-16 2003-03-13 Norman Latov Detection of anti-glycolipid antibodies by latex agglutination assay
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
WO2004065400A1 (en) 2003-01-20 2004-08-05 Glykos Finland Oy Novel binding epitopes for helicobacter pylori and use thereof
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
US20070258986A1 (en) 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
US20050187171A1 (en) 2003-11-19 2005-08-25 Glycomimetics, Inc. Glycomimetic antagonists for both E-and P-selectins
US7361644B2 (en) 2003-11-19 2008-04-22 Glycomimetics, Inc. Specific antagonist for both E- and P-selectins
US20050272097A1 (en) 2004-02-18 2005-12-08 Emanuel Calenoff Methods and compositions for detecting and treating autoimmune diseases
CA2557989C (en) 2004-03-04 2013-04-23 Progen Industries Limited Sulfated oligosaccharide derivatives
EP1761550A2 (en) 2004-05-26 2007-03-14 California Institute of Technology Small molecule stimulators of neuronal growth
CN101123990A (zh) 2004-10-01 2008-02-13 Mida科技有限公司 包含抗原和佐剂的纳米颗粒，和免疫原性结构
AU2005291058B2 (en) 2004-10-01 2011-09-29 Midatech Limited Nanoparticles comprising antigens and adjuvants and immunogenic structure
WO2006068720A2 (en) 2004-11-12 2006-06-29 The Brigham And Women's Hospital, Inc. Hematopoietic cell selectin ligand polypeptides and methods of use thereof
US7884260B2 (en) 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
JP4619873B2 (ja) * 2005-06-20 2011-01-26 独立行政法人産業技術総合研究所 グルクロニル硫酸化２糖誘導体
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
WO2007100699A2 (en) 2006-02-24 2007-09-07 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
WO2007120815A2 (en) 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
GB0610350D0 (en) 2006-05-25 2006-07-05 Univ Liverpool prevention and/or treatment of neuodegenerative disorders
US8420593B1 (en) 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
US20090175792A1 (en) 2006-06-23 2009-07-09 Glycomimetics, Inc. Glycomimetic inhibitors of siglec-8
JP5695317B2 (ja) 2006-09-05 2015-04-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗体媒介性ニューロパシーを処置するための方法および組成物
GB0622688D0 (en) 2006-11-14 2006-12-27 Diosamine Dev Corp Novel compounds
US20080220988A1 (en) 2007-03-07 2008-09-11 Ada Technologies, Inc. Preparing carbohydrate microarrays and conjugated nanoparticles
EP2842570B1 (en) 2007-03-07 2020-05-06 UTI Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
WO2008151847A1 (en) 2007-06-13 2008-12-18 Max-Delbrück-Centrum für Molekulare Medizin Autoantibody binding peptides and their use for the treatment of vascular diseases
EP2183251A1 (en) 2007-08-02 2010-05-12 Antisoma Ventures Limited Indazole compounds for treating inflammatory disorders, demyelinating disorders and cancers
BRPI0820960B8 (pt) 2007-12-05 2021-05-25 Abivax composição, composição farmacêutica, e uso da composição
WO2009102820A2 (en) 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
US9119866B2 (en) 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
AU2009234266B2 (en) 2008-04-11 2015-08-06 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US7981625B2 (en) 2008-04-15 2011-07-19 The Board Of Trustees Of The Leland Stanford Junior University Prostate cancer glycan markers and autoantibody signatures
US20120190581A1 (en) 2009-08-25 2012-07-26 The Johns Hopkins University Detection of Auto-Antibodies to Specific Glycans as Diagnostic Tests for Autoimmune Diseases
US20110105389A1 (en) * 2009-10-30 2011-05-05 Hoveyda Hamid R Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
WO2011101870A1 (en) 2010-02-22 2011-08-25 Transgene Biotek Ltd. Fusion proteins for the treatment of multiple sclerosis and other autoimmune diseases
WO2011156774A2 (en) 2010-06-11 2011-12-15 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
CN103608032A (zh) 2010-12-15 2014-02-26 基督科学教育协会 用于抑制免疫应答的方法
WO2013044044A2 (en) 2011-09-23 2013-03-28 President And Fellows Of Harvard College Methods of treating fatty liver disease with helminth-derived glycan-containing compounds
EP2698636A1 (en) 2012-08-13 2014-02-19 Fundació Institut d'Investigació Biomèdica de Bellvitge Methods and reagents for prevention and/or treatment of transplant rejection
WO2014027302A1 (en) 2012-08-16 2014-02-20 Pfizer Inc. Glycoconjugation processes and compositions
EP2727597A1 (en) 2012-11-06 2014-05-07 Centre National de la Recherche Scientifique (CNRS) Glucose responsive hydrogel comprising pba-grafted hyaluronic acid (ha)
CN105324116B (zh) 2013-04-26 2019-03-29 新加坡科技研究局 调适具有聚脯氨酸支架的生物聚合物的多价相互作用
WO2015007326A1 (en) 2013-07-18 2015-01-22 Institut D'investigació Biomèdica De Bellvitge (Idibell) Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases
WO2015116775A1 (en) 2014-01-30 2015-08-06 Trudeau Institute Nanoparticles for immune stimulation
DK3116887T3 (da) 2014-03-13 2021-04-26 Univ Basel Carbonhydratligander, der binder til igm-antistoffer mod myelin-associeret glykoprotein
CN108026134A (zh) 2015-09-16 2018-05-11 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体

Also Published As

Publication number Publication date
US20180327438A1 (en) 2018-11-15
SG11201607484RA (en) 2016-10-28
US10662212B2 (en) 2020-05-26
DK3116887T3 (da) 2021-04-26
HRP20210562T1 (hr) 2021-05-14
IL247355B (en) 2020-09-30
US20220185838A1 (en) 2022-06-16
EP3116887B1 (en) 2021-02-17
HUE054034T2 (hu) 2021-08-30
EP3116887A1 (en) 2017-01-18
NZ724236A (en) 2021-06-25
RU2760005C2 (ru) 2021-11-22
CY1124344T1 (el) 2022-07-22
ES2865148T3 (es) 2021-10-15
LT3116887T (lt) 2021-05-25
RU2016134035A (ru) 2018-04-13
EP3915999A1 (en) 2021-12-01
AU2015228870B2 (en) 2019-08-29
PL3116887T3 (pl) 2021-09-06
IL247355A0 (en) 2016-11-30
AU2019271964A1 (en) 2019-12-19
CA2940579A1 (en) 2015-09-17
CN106103461B (zh) 2019-05-10
US20210061838A1 (en) 2021-03-04
CN106103461A (zh) 2016-11-09
KR20160132034A (ko) 2016-11-16
MX2016011859A (es) 2017-05-12
RS61722B1 (sr) 2021-05-31
WO2015136027A1 (en) 2015-09-17
US20170022239A1 (en) 2017-01-26
SI3116887T1 (sl) 2021-06-30
JP2017509629A (ja) 2017-04-06
AU2019271964B2 (en) 2021-07-01
US11220523B2 (en) 2022-01-11
JP6502374B2 (ja) 2019-04-17
RU2016134035A3 (pt) 2018-10-25
US9994605B2 (en) 2018-06-12
AU2015228870A1 (en) 2016-09-29
CN110204582A (zh) 2019-09-06

Similar Documents

Publication Publication Date Title
IL247355A0 (en) Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
IL285287A (en) Antibodies to tigit
IL282403B1 (en) Antibodies against pd-1
IL284336B (en) Treatment using antibodies that bind to ctla4
HK1252262A1 (zh) 結合抗糖鞘脂糖蛋白表位抗體的碳水化合物配體
IL261188A (en) Antibodies against tigit
IL251963A0 (en) Anti-1-pd antibodies
HK1217958A1 (zh) 四價雙特異性抗體
HK1256300A1 (zh) 特異性地結合至tl1a的抗體
IL251676A0 (en) Antibodies that bind to ccr6 and their uses
PL2970503T3 (pl) Przeciwciała monoklonalne przeciw-(+) --metamfetaminie
SG11201604503XA (en) Cytotoxic antibody
GB201419080D0 (en) Anti-PD-1 antibodies
GB201419087D0 (en) Anti-PD-1 antibodies